- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06064097
- Procès original
Une étude utilisant un nouveau médicament, le nivolumab, en association avec des médicaments de chimiothérapie pour traiter un type de cancer appelé carcinome nasopharyngé (NPC)
Une étude de phase 2 utilisant la chimio-immunothérapie avec la gemcitabine, le cisplatine et le nivolumab dans le carcinome nasopharyngé (NPC) nouvellement diagnostiqué
This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Researchers want to find out what effects, good and/or bad, adding nivolumab to chemotherapy has on patients with newly diagnosed NPC. In addition, they want to find out if children with NPC may be treated with less radiation therapy and whether this decreases the side effects of therapy.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
- Autre: Quality-of-Life Assessment
- Médicament: Cisplatin
- Procédure: Biospecimen Collection
- Procédure: Computed Tomography
- Procédure: Magnetic Resonance Imaging
- Autre: Questionnaire Administration
- Procédure: Echocardiography Test
- Procédure: Multigated Acquisition Scan
- Procédure: Positron Emission Tomography
- Biologique: Nivolumab
- Médicament: Gemcitabine
- Procédure: Biopsy Procedure
- Procédure: Chest Radiography
- Autre: Electronic Health Record Review
- Radiation: Radiation Therapy
- Autre: Fluciclovine F18
- Procédure: X-Ray Imaging
Description détaillée
PRIMARY OBJECTIVE:
I. To evaluate safety of combining chemotherapy (cisplatin and gemcitabine) with an anti-PD1 immune checkpoint inhibitor (nivolumab) in children, adolescents and young adults with nasopharyngeal carcinoma (NPC) by determining the rate of Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher immune related adverse events (irAEs).
SECONDARY OBJECTIVES:
I. To estimate the 2-year event-free survival (EFS) of children, adolescents and young adults with NPC who are treated with induction chemoimmunotherapy (CIT), followed by consolidation chemoradioimmunotherapy (CRIT, cisplatin, nivolumab and response-adjusted, dose de-escalated radiation therapy), and nivolumab maintenance therapy.
II. To evaluate the objective response rate (ORR) including complete responders and partial responders (complete response [CR] + partial response [PR]) of neoadjuvant CIT.
III. To evaluate feasibility of combining chemotherapy (cisplatin and gemcitabine) with an anti-PD1 immune checkpoint inhibitor (nivolumab) in children, adolescents and young adults with nasopharyngeal carcinoma (NPC).
IV. To evaluate the cumulative incidence of local and distant relapse.
EXPLORATORY OBJECTIVES:
I. To estimate 5-year EFS and overall survival (OS) of children with NPC who are treated with induction CIT followed by consolidation CRIT, and nivolumab maintenance therapy.
II. To compare response assessed by fludeoxyglucose F18 (FDG) positron emission tomography (PET) versus magnetic resonance imaging (MRI).
III. To determine treatment outcomes for patients treated with radiation per protocol versus (vs) deviation.
IV. To evaluate outcomes comparing patients receiving intensity modulated radiation therapy (IMRT) to proton therapy.
V. To objectively measure both acute and long-term toxicity including immune related adverse events and radiation late effects.
VI. To evaluate swallowing dysfunction using patient reported outcome (PRO) measures for children and adults throughout the protocol for up to 5 years.
VII. To evaluate quality of life (QOL) using Patient-Reported Outcomes Measurement Information System (PROMIS) multidimensional questionnaire throughout the protocol for up to 5 years.
VIII. To correlate the lymphocyte to monocyte ratio on complete blood counts (CBCs) with treatment response and outcomes.
IX. To collect and bank specimens (including tumor and blood) for future research studies.
X. To compare dental x-rays in patients prior to radiation and 1 year post radiation to evaluate for dental caries and bone health.
OUTLINE:
INDUCTION THERAPY: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1 of each cycle, gemcitabine IV over 30 minutes on days 1 and 8 of each cycle, and cisplatin IV over 3-6 hours on day 1 of each cycle. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity.
CONSOLIDATION THERAPY: Patients receive nivolumab IV over 30 minutes on day 1 of each cycle and cisplatin IV over 3-6 hours on day 1 of cycles 1-2. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive concurrent radiation therapy on trial.
MAINTENANCE THERAPY: Patients receive nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
Patients also undergo echocardiography (ECHO) or multigated acquisition scan (MUGA) during screening and as clinically indicated on trial. Patients undergo MRI, FDG PET, and computed tomography (CT) throughout the trial and chest x-ray during follow-up. Patients also undergo dental x-ray imaging on the trial. Patients may optionally undergo tissue biopsy and blood sample collection during screening and on trial.
After completion of study treatment, patients are followed up every 3 months for 12 months, every 6 months until 24 months off therapy, and then yearly until 5 years off therapy.
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
New South Wales
-
Hunter Regional Mail Centre, New South Wales, Australie, 2310
- Recrutement
- John Hunter Children's Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: (02) 4985 5180
-
Chercheur principal:
- Kristy McCarthy
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T3B 6A8
- Recrutement
- Alberta Children's Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 403-220-6898
- E-mail: research4kids@ucalgary.ca
-
Chercheur principal:
- Victor A. Lewis
-
Edmonton, Alberta, Canada, T6G 2B7
- Recrutement
- University of Alberta Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 780-407-8798
- E-mail: pedsoncologyresearch@ahs.ca
-
Chercheur principal:
- Sarah J. McKillop
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- Recrutement
- Hospital for Sick Children
-
Contact:
- Site Public Contact
- Numéro de téléphone: 416-813-7654
- E-mail: ask.CRS@sickkids.ca
-
Chercheur principal:
- Avram E. Denburg
-
-
Quebec
-
Montreal, Quebec, Canada, H3H 1P3
- Recrutement
- The Montreal Children's Hospital of the MUHC
-
Contact:
- Site Public Contact
- Numéro de téléphone: 514-412-4445
- E-mail: info@thechildren.com
-
Chercheur principal:
- Stephanie Mourad
-
Montreal, Quebec, Canada, H3T 1C5
- Recrutement
- Centre Hospitalier Universitaire Sainte-Justine
-
Chercheur principal:
- Monia Marzouki
-
Contact:
- Site Public Contact
- Numéro de téléphone: 514-345-4931
- E-mail: yvan.samson@umontreal.ca
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Recrutement
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
Contact:
- Site Public Contact
- Numéro de téléphone: 819-820-6480
- E-mail: crcinformation.chus@ssss.gouv.qc.ca
-
Chercheur principal:
- Stephanie Vairy
-
-
-
-
-
Christchurch, Nouvelle-Zélande, 8011
- Recrutement
- Christchurch Hospital
-
Chercheur principal:
- Tristan Pettit
-
Contact:
- Site Public Contact
- Numéro de téléphone: 03 364 0640
-
-
Auckland
-
Grafton, Auckland, Nouvelle-Zélande, 1145
- Recrutement
- Starship Children's Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 0800 728 436
-
Chercheur principal:
- Leander D. Timothy
-
-
-
-
-
San Juan, Porto Rico, 00926
- Recrutement
- University Pediatric Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 787-474-0333
-
Chercheur principal:
- Maria E. Echevarria
-
-
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35233
- Recrutement
- Children's Hospital of Alabama
-
Contact:
- Site Public Contact
- Numéro de téléphone: 205-638-9285
- E-mail: oncologyresearch@peds.uab.edu
-
Chercheur principal:
- Jamie M. Aye
-
-
Arizona
-
Phoenix, Arizona, États-Unis, 85016
- Recrutement
- Phoenix Childrens Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 602-546-0920
-
Chercheur principal:
- Alok K. Kothari
-
-
Arkansas
-
Little Rock, Arkansas, États-Unis, 72202-3591
- Recrutement
- Arkansas Children's Hospital
-
Chercheur principal:
- Michael W. Bishop
-
Contact:
- Site Public Contact
- Numéro de téléphone: 501-364-7373
-
-
California
-
Downey, California, États-Unis, 90242
- Recrutement
- Kaiser Permanente Downey Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 626-564-3455
-
Chercheur principal:
- Robert M. Cooper
-
Loma Linda, California, États-Unis, 92354
- Recrutement
- Loma Linda University Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 909-558-4050
-
Chercheur principal:
- Albert Kheradpour
-
Los Angeles, California, États-Unis, 90027
- Recrutement
- Children's Hospital Los Angeles
-
Chercheur principal:
- Rachana Shah
-
Contact:
- Site Public Contact
- Numéro de téléphone: 323-361-4110
-
Madera, California, États-Unis, 93636
- Recrutement
- Valley Children's Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 559-353-3000
- E-mail: Research@valleychildrens.org
-
Chercheur principal:
- Ruetima Titapiwatanakun
-
Oakland, California, États-Unis, 94611
- Recrutement
- Kaiser Permanente-Oakland
-
Contact:
- Site Public Contact
- Numéro de téléphone: 877-642-4691
- E-mail: Kpoct@kp.org
-
Chercheur principal:
- Aarati V. Rao
-
Oakland, California, États-Unis, 94609
- Recrutement
- UCSF Benioff Children's Hospital Oakland
-
Chercheur principal:
- Jennifer G. Michlitsch
-
Contact:
- Site Public Contact
- Numéro de téléphone: 510-428-3264
- E-mail: PedOncRschOAK@ucsf.edu
-
San Diego, California, États-Unis, 92123
- Recrutement
- Rady Children's Hospital - San Diego
-
Contact:
- Site Public Contact
- Numéro de téléphone: 858-966-5934
-
Chercheur principal:
- William D. Roberts
-
San Francisco, California, États-Unis, 94158
- Recrutement
- UCSF Medical Center-Mission Bay
-
Contact:
- Site Public Contact
- Numéro de téléphone: 877-827-3222
- E-mail: cancertrials@ucsf.edu
-
Chercheur principal:
- Arun A. Rangaswami
-
-
Colorado
-
Aurora, Colorado, États-Unis, 80045
- Recrutement
- Children's Hospital Colorado
-
Chercheur principal:
- Navin R. Pinto
-
Contact:
- Site Public Contact
- Numéro de téléphone: 303-764-5056
- E-mail: josh.b.gordon@nsmtp.kp.org
-
-
Connecticut
-
Hartford, Connecticut, États-Unis, 06106
- Recrutement
- Connecticut Children's Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 860-545-9981
-
Chercheur principal:
- Michael S. Isakoff
-
-
Delaware
-
Wilmington, Delaware, États-Unis, 19803
- Recrutement
- Alfred I duPont Hospital for Children
-
Contact:
- Site Public Contact
- Numéro de téléphone: 302-651-5572
- E-mail: Allison.bruce@nemours.org
-
Chercheur principal:
- Sridhi Patel
-
-
District of Columbia
-
Washington D.C., District of Columbia, États-Unis, 20010
- Recrutement
- Children's National Medical Center
-
Chercheur principal:
- Jeffrey S. Dome
-
Contact:
- Site Public Contact
- Numéro de téléphone: 202-476-2800
- E-mail: OncCRC_OnCall@childrensnational.org
-
-
Florida
-
Gainesville, Florida, États-Unis, 32610
- Recrutement
- UF Health Cancer Institute - Gainesville
-
Contact:
- Site Public Contact
- Numéro de téléphone: 352-273-8010
- E-mail: cancer-center@ufl.edu
-
Chercheur principal:
- Brian Stover
-
Jacksonville, Florida, États-Unis, 32207
- Recrutement
- Nemours Children's Clinic-Jacksonville
-
Contact:
- Site Public Contact
- Numéro de téléphone: 302-651-5572
- E-mail: Allison.bruce@nemours.org
-
Chercheur principal:
- Sridhi Patel
-
Miami, Florida, États-Unis, 33155
- Recrutement
- Nicklaus Children's Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 888-624-2778
-
Chercheur principal:
- Ziad A. Khatib
-
Orlando, Florida, États-Unis, 32806
- Recrutement
- Arnold Palmer Hospital for Children
-
Contact:
- Site Public Contact
- Numéro de téléphone: 321-841-5357
- E-mail: Jennifer.spinelli@orlandohealth.com
-
Chercheur principal:
- Zhongbo Hu
-
Orlando, Florida, États-Unis, 32827
- Recrutement
- Nemours Children's Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 302-651-5572
- E-mail: Allison.bruce@nemours.org
-
Chercheur principal:
- Sridhi Patel
-
Pensacola, Florida, États-Unis, 32504
- Recrutement
- Nemours Children's Clinic - Pensacola
-
Contact:
- Site Public Contact
- E-mail: helpdesk@childrensoncologygroup.org
-
Chercheur principal:
- Jeffrey H. Schwartz
-
Tampa, Florida, États-Unis, 33607
- Recrutement
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
Contact:
- Site Public Contact
- Numéro de téléphone: 813-357-0849
- E-mail: jennifer.manns@baycare.org
-
Chercheur principal:
- Don E. Eslin
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30329
- Recrutement
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
Chercheur principal:
- Sarah G. Mitchell
-
Contact:
- Site Public Contact
- Numéro de téléphone: 404-785-0232
- E-mail: Olivia.Floyd@choa.org
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60611
- Recrutement
- Lurie Children's Hospital-Chicago
-
Chercheur principal:
- Amy L. Walz
-
Contact:
- Site Public Contact
- Numéro de téléphone: 773-880-4562
-
Chicago, Illinois, États-Unis, 60637
- Suspendu
- University of Chicago Comprehensive Cancer Center
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46202
- Recrutement
- Riley Hospital for Children
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-248-1199
-
Chercheur principal:
- Marissa Just
-
-
Kentucky
-
Lexington, Kentucky, États-Unis, 40536
- Pas encore de recrutement
- University of Kentucky/Markey Cancer Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 859-257-3379
-
Chercheur principal:
- James T. Badgett
-
-
Louisiana
-
New Orleans, Louisiana, États-Unis, 70118
- Recrutement
- Children's Hospital New Orleans
-
Chercheur principal:
- Maria C. Velez-Yanguas
-
Contact:
- Site Public Contact
- Numéro de téléphone: 504-894-5377
-
-
Maine
-
Scarborough, Maine, États-Unis, 04074
- Recrutement
- Maine Children's Cancer Program
-
Chercheur principal:
- Aaron R. Weiss
-
Contact:
- Site Public Contact
- Numéro de téléphone: 207-396-8670
- E-mail: clinicalresearch@mainehealth.org
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21287
- Recrutement
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 410-955-8804
- E-mail: jhcccro@jhmi.edu
-
Chercheur principal:
- Robyn D. Gartrell
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02215
- Recrutement
- Dana-Farber Cancer Institute
-
Chercheur principal:
- Allison F. O'Neill
-
Contact:
- Site Public Contact
- Numéro de téléphone: 877-442-3324
-
-
Michigan
-
Grand Rapids, Michigan, États-Unis, 49503
- Recrutement
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Chercheur principal:
- Kathleen Y. Butler
-
-
Minnesota
-
Rochester, Minnesota, États-Unis, 55905
- Recrutement
- Mayo Clinic in Rochester
-
Contact:
- Site Public Contact
- Numéro de téléphone: 855-776-0015
-
Chercheur principal:
- Peter Schoettler
-
-
Mississippi
-
Jackson, Mississippi, États-Unis, 39216
- Recrutement
- University of Mississippi Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 601-815-6700
-
Chercheur principal:
- Amanda Strobel
-
-
Missouri
-
Kansas City, Missouri, États-Unis, 64108
- Recrutement
- Children's Mercy Hospitals and Clinics
-
Chercheur principal:
- Keith J. August
-
Contact:
- Site Public Contact
- Numéro de téléphone: 816-302-6808
- E-mail: COGResearchGroup@cmh.edu
-
St Louis, Missouri, États-Unis, 63110
- Recrutement
- Washington University School of Medicine
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-600-3606
- E-mail: info@siteman.wustl.edu
-
Chercheur principal:
- Frederick S. Huang
-
-
Nebraska
-
Omaha, Nebraska, États-Unis, 68114
- Recrutement
- Children's Hospital and Medical Center of Omaha
-
Contact:
- Site Public Contact
- Numéro de téléphone: 402-955-3949
-
Chercheur principal:
- Jill C. Beck
-
Omaha, Nebraska, États-Unis, 68198
- Recrutement
- University of Nebraska Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 402-559-6941
- E-mail: unmcrsa@unmc.edu
-
Chercheur principal:
- Jill C. Beck
-
-
New Jersey
-
Hackensack, New Jersey, États-Unis, 07601
- Recrutement
- Hackensack University Medical Center
-
Chercheur principal:
- Katharine Offer
-
Contact:
- Site Public Contact
- Numéro de téléphone: 551-996-2897
-
Neptune City, New Jersey, États-Unis, 07753
- Recrutement
- Jersey Shore Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 732-776-4240
-
Chercheur principal:
- Katharine Offer
-
New Brunswick, New Jersey, États-Unis, 08903
- Recrutement
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Chercheur principal:
- Scott Moerdler
-
Contact:
- Site Public Contact
- Numéro de téléphone: 732-235-8675
-
Newark, New Jersey, États-Unis, 07112
- Recrutement
- Newark Beth Israel Medical Center
-
Chercheur principal:
- Scott Moerdler
-
Contact:
- Site Public Contact
- Numéro de téléphone: 973-926-7230
- E-mail: Christine.Kosmides@rwjbh.org
-
Chercheur principal:
- Teena Bhatla
-
-
New York
-
Albany, New York, États-Unis, 12208
- Recrutement
- Albany Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 518-262-5513
-
Chercheur principal:
- Lauren R. Weintraub
-
The Bronx, New York, États-Unis, 10467
- Recrutement
- Montefiore Medical Center - Moses Campus
-
Contact:
- Site Public Contact
- Numéro de téléphone: 718-379-6866
- E-mail: eskwak@montefiore.org
-
Chercheur principal:
- Alice Lee
-
-
North Carolina
-
Charlotte, North Carolina, États-Unis, 28203
- Recrutement
- Carolinas Medical Center/Levine Cancer Institute
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-804-9376
-
Chercheur principal:
- Joel A. Kaplan
-
Durham, North Carolina, États-Unis, 27710
- Recrutement
- Duke University Medical Center
-
Chercheur principal:
- Jessica M. Sun
-
Contact:
- Site Public Contact
- Numéro de téléphone: 888-275-3853
-
Greenville, North Carolina, États-Unis, 27834
- Recrutement
- East Carolina University
-
Contact:
- Site Public Contact
- Numéro de téléphone: 252-744-1015
- E-mail: eubankss@ecu.edu
-
Chercheur principal:
- Andrea R. Whitfield
-
Winston-Salem, North Carolina, États-Unis, 27157
- Recrutement
- Wake Forest University Health Sciences
-
Contact:
- Site Public Contact
- Numéro de téléphone: 336-713-6771
-
Chercheur principal:
- Sarah Supples
-
-
North Dakota
-
Fargo, North Dakota, États-Unis, 58122
- Recrutement
- Sanford Broadway Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 701-323-5760
- E-mail: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Chercheur principal:
- Samuel J. Milanovich
-
-
Ohio
-
Cincinnati, Ohio, États-Unis, 45229
- Recrutement
- Cincinnati Children's Hospital Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 513-636-2799
- E-mail: cancer@cchmc.org
-
Chercheur principal:
- Brian K. Turpin
-
Cleveland, Ohio, États-Unis, 44106
- Recrutement
- Rainbow Babies and Childrens Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 216-844-5437
-
Chercheur principal:
- Duncan S. Stearns
-
Columbus, Ohio, États-Unis, 43205
- Recrutement
- Nationwide Children's Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 614-722-6039
- E-mail: Melinda.Triplet@nationwidechildrens.org
-
Chercheur principal:
- Mark A. Ranalli
-
Dayton, Ohio, États-Unis, 45404
- Recrutement
- Dayton Children's Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-228-4055
-
Chercheur principal:
- Jordan M. Wright
-
-
Oklahoma
-
Oklahoma City, Oklahoma, États-Unis, 73104
- Recrutement
- University of Oklahoma Health Sciences Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 405-271-8777
- E-mail: ou-clinical-trials@ouhsc.edu
-
Chercheur principal:
- Rene Y. McNall-Knapp
-
-
Pennsylvania
-
Allentown, Pennsylvania, États-Unis, 18103
- Recrutement
- Lehigh Valley Hospital-Cedar Crest
-
Contact:
- Site Public Contact
- Numéro de téléphone: 610-402-9543
- E-mail: Morgan_M.Horton@lvhn.org
-
Chercheur principal:
- Jacob A. Troutman
-
Hershey, Pennsylvania, États-Unis, 17033
- Recrutement
- Penn State Children's Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 717-531-6012
-
Chercheur principal:
- Lisa M. McGregor
-
Philadelphia, Pennsylvania, États-Unis, 19104
- Recrutement
- Children's Hospital of Philadelphia
-
Contact:
- Site Public Contact
- Numéro de téléphone: 267-425-5544
- E-mail: CancerTrials@email.chop.edu
-
Chercheur principal:
- Theodore W. Laetsch
-
Pittsburgh, Pennsylvania, États-Unis, 15224
- Recrutement
- Children's Hospital of Pittsburgh of UPMC
-
Contact:
- Site Public Contact
- Numéro de téléphone: 412-692-8570
- E-mail: jean.tersak@chp.edu
-
Chercheur principal:
- Brittani K. Seynnaeve
-
-
South Carolina
-
Columbia, South Carolina, États-Unis, 29203
- Recrutement
- Prisma Health Richland Hospital
-
Chercheur principal:
- Stuart L. Cramer
-
Contact:
- Site Public Contact
- Numéro de téléphone: 864-522-4317
- E-mail: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, États-Unis, 29605
- Recrutement
- BI-LO Charities Children's Cancer Center
-
Chercheur principal:
- Aniket Saha
-
Contact:
- Site Public Contact
- Numéro de téléphone: 864-522-4317
- E-mail: Kim.Williams3@prismahealth.org
-
-
South Dakota
-
Sioux Falls, South Dakota, États-Unis, 57117-5134
- Recrutement
- Sanford USD Medical Center - Sioux Falls
-
Contact:
- Site Public Contact
- Numéro de téléphone: 605-312-3320
- E-mail: OncologyClinicalTrialsSF@SanfordHealth.org
-
Chercheur principal:
- Jordan Fritch-Hanson
-
-
Tennessee
-
Memphis, Tennessee, États-Unis, 38105
- Recrutement
- Saint Jude Children's Research Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 888-226-4343
- E-mail: referralinfo@stjude.org
-
Chercheur principal:
- Catherine G. Lam
-
Nashville, Tennessee, États-Unis, 37232
- Recrutement
- Vanderbilt University/Ingram Cancer Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-811-8480
-
Chercheur principal:
- Scott C. Borinstein
-
Nashville, Tennessee, États-Unis, 37203
- Recrutement
- The Children's Hospital at TriStar Centennial
-
Contact:
- Site Public Contact
- Numéro de téléphone: 615-342-1919
-
Chercheur principal:
- Clinton M. Carroll
-
-
Texas
-
Austin, Texas, États-Unis, 78723
- Recrutement
- Dell Children's Medical Center of Central Texas
-
Contact:
- Site Public Contact
- Numéro de téléphone: 512-628-1902
- E-mail: TXAUS-DL-SFCHemonc.research@ascension.org
-
Chercheur principal:
- Shannon M. Cohn
-
Dallas, Texas, États-Unis, 75390
- Recrutement
- UT Southwestern/Simmons Cancer Center-Dallas
-
Contact:
- Site Public Contact
- Numéro de téléphone: 214-648-7097
- E-mail: canceranswerline@UTSouthwestern.edu
-
Chercheur principal:
- Avanthi T. Shah
-
Fort Worth, Texas, États-Unis, 76104
- Recrutement
- Cook Children's Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 682-885-2103
- E-mail: CookChildrensResearch@cookchildrens.org
-
Chercheur principal:
- Chelsee Greer
-
Houston, Texas, États-Unis, 77030
- Recrutement
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 713-798-1354
- E-mail: burton@bcm.edu
-
Chercheur principal:
- Mehmet F. Okcu
-
Houston, Texas, États-Unis, 77030
- Recrutement
- UT MD Anderson Cancer Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 866-632-6789
- E-mail: askmdanderson@mdanderson.org
-
Chercheur principal:
- Najat C. Daw
-
San Antonio, Texas, États-Unis, 78207
- Recrutement
- Children's Hospital of San Antonio
-
Contact:
- Site Public Contact
- Numéro de téléphone: 210-704-2894
- E-mail: bridget.medina@christushealth.org
-
Chercheur principal:
- Julie Voeller
-
-
Virginia
-
Charlottesville, Virginia, États-Unis, 22908
- Recrutement
- University of Virginia Cancer Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 434-243-6303
- E-mail: uvacancertrials@hscmail.mcc.virginia.edu
-
Chercheur principal:
- Brian C. Belyea
-
Norfolk, Virginia, États-Unis, 23507
- Recrutement
- Children's Hospital of The King's Daughters
-
Contact:
- Site Public Contact
- Numéro de téléphone: 757-668-7243
- E-mail: CCBDCresearch@chkd.org
-
Chercheur principal:
- Melissa S. Mark
-
Richmond, Virginia, États-Unis, 23298
- Recrutement
- VCU Massey Comprehensive Cancer Center
-
Chercheur principal:
- Madhu S. Gowda
-
Contact:
- Site Public Contact
- Numéro de téléphone: 804-628-6430
- E-mail: CTOclinops@vcu.edu
-
-
Washington
-
Seattle, Washington, États-Unis, 98105
- Recrutement
- Seattle Children's Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 866-987-2000
-
Chercheur principal:
- Sarah E. Leary
-
Tacoma, Washington, États-Unis, 98405
- Recrutement
- Mary Bridge Children's Hospital and Health Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 253-403-1461
- E-mail: research@multicare.org
-
Chercheur principal:
- Robert G. Irwin
-
-
Wisconsin
-
Milwaukee, Wisconsin, États-Unis, 53226
- Recrutement
- Children's Hospital of Wisconsin
-
Chercheur principal:
- Angela Steineck
-
Contact:
- Site Public Contact
- Numéro de téléphone: 414-955-4727
- E-mail: MACCCTO@mcw.edu
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Patients must be ≤ 21 years of age at the time of study enrollment
-
Newly diagnosed American Joint Committee on Cancer (AJCC) (8th edition) stage II-IV nasopharyngeal carcinoma (NPC)
- Patients must have had histologic verification of the malignancy at original diagnosis
- Although submission of tumor tissue for the molecular characterization initiative is not required for eligibility, it is strongly recommended
-
Patients must have had histologic verification of the malignancy at original diagnosis
-
Although submission of tumor tissue for the molecular characterization initiative is not required for eligibility, it is strongly recommended
-
Patients must have a Lansky (for patients ≤ 16 years of age) or Karnofsky (for patients > 16 years of age) performance status score of ≥ 60%
-
Peripheral absolute neutrophil count (ANC) ≥ 1000/uL (within 7 days prior to start of protocol therapy)
-
Platelet count ≥ 100,000/uL (transfusion independent) (within 7 days prior to start of protocol therapy)
-
Creatinine clearance or radioisotope glomerular filtration rate (GFR) ≥ 60 mL/min/1.73 m^2 or (within 7 days prior to start of protocol therapy)
-
A serum creatinine based on age/sex (within 7 days prior to start of protocol therapy) Age: Maximum serum creatinine (mg/dL)
1 month to < 6 months: 0.4 mg/dL (male); 0.4 mg/dL (female) 6 months to < 1 year: 0.5 mg/dL (male); 0.5 mg/dL (female)
- to < 2 years: 0.6 mg/dL (male); 0.6 mg/dL (female)
- to < 6 years: 0.8 mg/dL (male); 0.8 mg/dL (female)
6 to < 10 years 1 mg/dL (male); 1 mg/dL (female) 10 to <13 years: 1.2 mg/dL (male); 1.2 mg/dL (female) 13 to < 16 years: 1.5 mg/dL (male); 1.4 mg/dL (female) â ¥ 16 years: 1.7 mg/dL (male); 1.4 mg/dL (female)
-
Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age, and (within 7 days prior to start of protocol therapy)
-
Serum glutamic-pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) ≤ 135 U/L* (within 7 days prior to start of protocol therapy)
- Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L
-
Shortening fraction of ≥ 27% by echocardiogram, or
-
Ejection fraction of ≥ 50% by radionuclide angiogram
-
No evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry > 94% if there is clinical indication for determination
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months and T-cell count above the lower limit of normal are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
Exclusion Criteria:
-
Patients who received prior radiotherapy to the head or neck
-
Patients who received prior chemotherapy or radiation for the treatment of any cancer in the last 3 years. These patients must also be in remission
-
Patients with a diagnosis of immunodeficiency
-
Patients with an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive agents). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- Note: Patients with well-controlled asthma and no need for systemic steroids for the treatment of asthma in the last 12 months will not be excluded
-
Patients with a condition requiring systemic treatment with either corticosteroids (> 0.25 mg/kg (10 mg) daily prednisone equivalent) within 14 days or other immunosuppressive medications within 30 days of enrollment. Inhaled or topical steroids, and adrenal replacement steroid doses > 0.25 mg/kg (10 mg) daily prednisone equivalent, are permitted in the absence of active autoimmune disease
-
Patients with a history of (non-infectious) pneumonitis that required steroids or current pneumonitis
-
Patients with detectable viral load of human immunodeficiency virus (HIV), hepatitis B or hepatitis C, or active tuberculosis
-
Patients who have undergone solid organ or allogeneic hematopoietic transplant at any time
-
Due to risks of fetal and teratogenic adverse events as seen in animal studies, a negative pregnancy test must be obtained in females of childbearing potential, defined as females who are post-menarchal. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
-
Females of childbearing potential that are sexually active must agree to either practice 2 medically accepted highly-effective methods of contraception at the same time or abstain from heterosexual intercourse from the time of signing the informed consent through 5 months after the last dose of nivolumab, 6 months after the last dose of gemcitabine, and 14 months after the last dose of cisplatin, whichever is longer
-
Males of childbearing potential that are sexually active must agree to either practice a medically accepted highly-effective methods of contraception or abstain from heterosexual intercourse from the time of signing the informed consent through 3 months after the last dose of gemcitabine, and 11 months after the last dose of cisplatin, whichever is longer
-
Lactating females are not eligible unless they have agreed not to breastfeed their infants starting with the first dose of study therapy through 5 months after the last dose of nivolumab
-
All patients and/or their parents or legal guardians must sign a written informed consent
-
All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Treatment (nivolumab, gemcitabine, cisplatin, radiation)
See Detailed Description |
Ancillary studies
Autres noms:
Given IV
Autres noms:
Undergo blood sample collection
Autres noms:
Undergo CT
Autres noms:
Undergo MRI
Autres noms:
Ancillary studies Undergo ECHO
Autres noms:
Undergo MUGA
Autres noms:
Undergo PET
Autres noms:
Given IV
Autres noms:
Given IV
Autres noms:
Undergo tissue biopsy
Autres noms:
Undergo chest x-ray
Autres noms:
Ancillary studies Receive radiation therapy
Autres noms:
Given IV
Autres noms:
Undergo dental x-ray
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of grade 3 or higher immune-related adverse events (irAE) during induction chemoimmunotherapy (CIT)
Délai: Until the end of consolidation therapy
|
Will be assessed by Common Terminology Criteria for Adverse Events (8th edition). IrAEs include diarrhea (noninfectious), colitis (noninfectious), pneumonitis (noninfectious), myocarditis, elevated alanine aminotransferase, elevated aspartate aminotransferase, pancreatitis, elevated blood bilirubin, hypophysitis and hyperthyroid considered possibly, probably, or definitely related to nivolumab. |
Until the end of consolidation therapy
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Event-free survival (EFS)
Délai: From date of enrollment to the earliest occurrence of date of relapse, disease progression, second malignant neoplasm or death due to any cause, assessed at 2 years
|
EFS along with the 95% confidence intervals will be estimated using the Kaplan-Meier method. The EFS will be reported separately for patients with non-metastatic disease and those with metastatic disease (if there are enough patients with metastatic disease enrolled). |
From date of enrollment to the earliest occurrence of date of relapse, disease progression, second malignant neoplasm or death due to any cause, assessed at 2 years
|
|
Objective response rate
Délai: At the end of induction CIT
|
Will be defined as the rate of responders among evaluable patients using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. |
At the end of induction CIT
|
|
Feasibility success of the induction regimen
Délai: At the end of induction CIT
|
Will be defined as the completion of three cycles of induction without delay of greater than 30 days for radiation initiation due to toxicity in 80% of patients. |
At the end of induction CIT
|
|
Cumulative incidence of local or distant relapse
Délai: Up to 5 years
|
Defined as a function of time since enrollment will be estimated by the method of Gray. |
Up to 5 years
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
EFS
Délai: At 5 years
|
Will be assessed using Kaplan-Meier estimates. |
At 5 years
|
|
Overall survival
Délai: From date of enrollment to death due to any cause or date of last follow-up, assessed at 5 years
|
Will be assessed using Kaplan-Meier estimates. |
From date of enrollment to death due to any cause or date of last follow-up, assessed at 5 years
|
|
Proportion of patients who achieve complete response
Délai: At the end of induction and maintenance
|
Will be assessed by retrospective central review by the proportion of patients who achieve complete response by magnetic resonance imaging using RECIST 1.1 criteria and the proportion of patients who achieve complete metabolic response using Positron Emission Tomography Response Criteria In Solid Tumors criteria at the end of induction and the end of maintenance based on central review will be presented. A two-way table of response assessments according to the two modalities will be constructed and McNemar's test will be performed to evaluate the concordance. |
At the end of induction and maintenance
|
|
Protocol deviation related to radiation therapy delivery
Délai: Up to 5 years
|
Will be assessed by retrospective central review. The effect of deviation, categorized as present or absent by the central reviewer, on the hazard of EFS will be estimated by Cox proportional hazard model. The hazard ratio will be reported along with 95% confidence interval. |
Up to 5 years
|
|
EFS in patients receiving intensity modulated radiation therapy with those who receive proton therapy
Délai: Up to 5 years
|
Will be assessed using a log-rank test. |
Up to 5 years
|
|
Incidence of grade 3 or higher adverse events
Délai: Up to 5 years
|
Will be assessed during protocol therapy. The incidence of these events will be reported for each toxicity term. Furthermore, the irAE and toxicity related to radiation will be summarized by toxicity term and will be presented separately for the on-protocol therapy period and long-term follow-up. |
Up to 5 years
|
|
Swallowing dysfunction
Délai: At baseline, during induction prior to start of chemoradioimmunotherapy (CRIT), each cycle throughout CRIT, within 3 months after maintenance and yearly at follow up, up to 5 years
|
Will be assessed using modified Functional Oral Intake Scale (FOIS) and pediatric Eating Assessment Tool (EAT)-10. The EAT-10 consists of 10 items scored from 0 (no impairment) to 4 (severe impairment). Total scores range from 0 to 40; higher scores indicate greater self-perceived impairment. Modified FOIS is an ordinal scale is a rating scale with 7 points for adults and 5 points in pediatrics. It is used to describe the feeding status and patients with dysphagia. Level 1 indicates inability to take anything by mouth while the highest point indicates full oral feeding. Will summarize responses from the modified FOIS and pediatric EAT-10 descriptively for each of these time points. A two-sided Wilcoxon rank-sum test will be performed to test the null hypothesis of equal score between two groups (who receive 54Gy versus 59.4Gy) at the end of the CRIT. Will evaluate the potential impact of other factors, as appropriate, such as baseline scores or disease stages for this analysis. |
At baseline, during induction prior to start of chemoradioimmunotherapy (CRIT), each cycle throughout CRIT, within 3 months after maintenance and yearly at follow up, up to 5 years
|
|
Quality of life
Délai: At baseline, during induction prior to start of CRIT, each cycle throughout CRIT, within 3 months after maintenance and yearly at follow up, up to 5 years
|
Will be assessed using Patient-Reported Outcomes Measurement Information System (PROMIS). PROMIS includes multiple measures such as physical function mobility, anxiety, depressive symptoms, fatigue, etc. PROMIS use a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation of that population. Higher T-score indicates more of the concept being measured. The numerical T scores of each domain will be summarized descriptively at every time point. |
At baseline, during induction prior to start of CRIT, each cycle throughout CRIT, within 3 months after maintenance and yearly at follow up, up to 5 years
|
|
Lymphocyte-to-monocyte ratio (LMR)
Délai: At baseline, pre-radiation/consolidation, and post-radiation pre-maintenance
|
Will be assessed the ratio calculated by dividing the absolute lymphocyte count by the absolute monocyte count from a complete blood count with differential analysis performed. Lymphocyte and monocyte counts will be collected at the following time points: baseline, pre-radiation/consolidation, and post-radiation pre-maintenance. Cox proportional hazards regression will be used to evaluate the association between baseline LMR and EFS. The hazard ratio will be reported with a 95% confidence interval. In addition, the LMR will be summarized descriptively by the evaluation time points. |
At baseline, pre-radiation/consolidation, and post-radiation pre-maintenance
|
|
Dental changes
Délai: At baseline (prior to radiation) and up to 1 post radiation
|
Will include dental caries and osteoradionecrosis. Dental caries will be quantified as the number of teeth with caries, and bone health will be evaluated as a categorical variable using 0 for no disease and a score of 1-4 to match stage of periodontal disease as described in 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions was co-presented by the American Academy of Periodontology and the European Federation of Periodontology staging framework. Changes over time will be evaluated using paired analyses. Given the small sample size, results will primarily be descriptive, with patient's dental caries and bone health data summarized using descriptive statistics. |
At baseline (prior to radiation) and up to 1 post radiation
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Robyn D Gartrell, Children's Oncology Group
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies stomatognathiques
- Tumeurs par site
- Tumeurs
- Tumeurs par type histologique
- Tumeurs de la tête et du cou
- Tumeurs, glandulaires et épithéliales
- Carcinome
- Maladies oto-rhino-laryngologiques
- Tumeurs pharyngées
- Tumeurs oto-rhino-laryngologiques
- Maladies nasopharyngées
- Maladies pharyngées
- Tumeurs du nasopharynx
- Carcinome du nasopharynx
- Acides aminés, peptides et protéines
- Protéines
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Techniques d'investigation
- Thérapeutique
- Techniques de laboratoire clinique
- Techniques et procédures de diagnostic
- Diagnostic
- Procédures chirurgicales, opératoires
- Techniques cytologiques
- Cytodiagnostic
- Phénomènes physiques
- Équipement et fournitures
- Anticorps, monoclonal, humanisé
- Anticorps, monoclonal
- Anticorps
- Immunoglobulines
- Immunoprotéines
- Protéines sanguines
- Globulines sériques
- Globulines
- Produits chimiques inorganiques
- Composés de chlore
- Composés d'azote
- Désoxycytidine
- Cytidine
- Nucléosides pyrimidine
- Pyrimidines
- Éléments
- Métaux
- Techniques de diagnostic, chirurgicale
- Techniques de chimie, analytique
- Analyse du spectre
- Métaux, lourds
- Composés en platine
- Phénomènes électromagnétiques
- Phénomènes magnétiques
- Éléments de transition
- Rayonnement électromagnétique
- Rayonnement, ionisant
- Nivolumab
- Gemcitabine
- Cisplatine
- Citrate de 1,2-diaminocyclohexaneplatine II
- Radiothérapie
- Radiation
- Biopsie
- Manipulation des échantillons
- Spectroscopie de résonance magnétique
- Platine
- Rayons X
- Phantomes, imagerie
- Fluciclovine F-18
Autres numéros d'identification d'étude
- NCI-2023-07208
- U10CA180886 (Subvention/contrat des NIH des États-Unis)
- NCI-2023-07208 (Identificateur de registre: CTRP (Clinical Trial Reporting Program))
- ARAR2221 (Autre identifiant: CTEP)
- ARAR2221 (Autre identifiant: Children's Oncology Group)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .